The growing
prevalence of chronic diseases and the incidence of novel diseases is expected
to boost the clinical
trials market. According to the World Heart Report 2023, over half a
billion people worldwide are affected by Cardiovascular Diseases (CVDs), which
caused over 20.5 million deaths in 2021. Furthermore, according to the
Parkinson’s Foundation, approximately 1 million individuals in the U.S.
currently suffer from Parkinson's Disease (PD), which is projected to increase
to over 1.2 million by 2030.
The prevalence
of rare or orphan diseases has garnered attention in recent years,
necessitating specialized clinical trials. As diseases become more varied and complex,
there is a heightened demand for specialized expertise in clinical trial
design, patient recruitment, and data analysis. Trial sponsors seek experts capable
of navigating the intricacies of diverse diseases. Thus, the aforementioned
factors are expected to drive the market demand.
Request
For Free Sample Report @ Clinical
Trials Market Report
From
Firsts to Finals: The Four Phases
·
Phase I: Phase I
clinical trials are the first stage of human testing for a new medical
intervention. They focus on evaluating its safety, determining the appropriate
dosage, and collecting initial data on how the body interacts with the
intervention.
·
Phase II: Phase II
clinical trial is a controlled study conducted on a relatively larger group of
patients to assess the safety and efficacy of a new medical intervention, such
as a drug or treatment.
·
Phase III: A Phase III
clinical trial involves a large-scale and rigorously controlled study conducted
to confirm and further evaluate the safety and effectiveness of a medical
intervention identified in Phase II.
·
Phase IV: A Phase IV
clinical trial, also known as post-marketing surveillance, occurs after a
medical product has received regulatory approval.
Top
Trends Streamlining Clinical Trials:
·
Rising Demand
for Personalized Medicine: Numerous
companies are focusing on the development of targeted therapies to cater to
specific genetic diseases. Clinical trials are pivotal in validating these
therapies, potentially leading to smaller, more specialized markets.
Furthermore, several regulatory authorities offer flexibility in trial designs,
with real-world evidence and favorable regulatory pathways for smaller patient populations,
positively influencing market growth.
·
Technological
Advancements: The
growing adoption of decentralized clinical trials and telemedicine
in clinical trials offers several advantages, which are expected to drive the overall
potential of the industry. Moreover, the integration of remote monitoring
technology enables continuous patient data collection outside clinical
settings. This real-time data improves trial accuracy, enhances patient
engagement, and allows more comprehensive insights into patient health.
·
Research &
Development Activities:
Collaborations between biopharmaceutical companies and CROs are expected to
impact the industry positively. Contract research organizations have seen a
major boost owing to rising R&D expenditures and pharmaceutical companies’ increasing
focus on cost containment. Several biopharmaceutical and medical device
companies are outsourcing their clinical trials to CROs to reduce product
development time and cost.
The
Final Diagnosis:
Clinical trials might seem like an intricate
world of complex processes but they are the bridge between ground-breaking
discoveries and life-saving treatments. By participating in such trials,
individuals can contribute to medical progress, thereby paving the way for a
healthier future. Even the smallest contribution can help make a world of great
difference!
Recent
Developments
·
In
August 2023, Parexel & Partex entered a strategic partnership aimed at
utilizing Artificial Intelligence (AI)-driven solutions to expedite the process
of drug discovery and development for biopharmaceutical clients globally. The
collaboration aimed to reduce risks associated with the assets in their respective
portfolios.
·
In
August 2023, Novo Nordisk announced to acquire Inversago Pharma. This
acquisition was part of Novo Nordisk's strategic efforts to develop new
therapies targeting individuals with obesity, diabetes, and other significant
metabolic diseases
·
In
April 2022, Charles River Laboratories International, Inc. disclosed its
acquisition of Explora BioLabs Holdings, Inc., a leading provider of contract
vivarium research services.
About
Us:
Grand
View Research, Inc. is a U.S. based market research and consulting company,
registered in the State of California and headquartered in San Francisco. The
company provides syndicated research reports, customized research reports, and
consulting services. To help clients make informed business decisions, the
company offers market intelligence studies ensuring relevant and fact-based
research across a range of industries including technology, chemicals,
materials, healthcare and energy.
Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: sales@grandviewresearch.com
For More Information: https://www.grandviewresearch.com
No comments:
Post a Comment